 Timothy Ung
Concepts (134)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Brain Neoplasms | 12 | 2022 | 966 | 1.990 |
Why?
| | Neuroma, Acoustic | 3 | 2023 | 32 | 1.760 |
Why?
| | Meningioma | 5 | 2022 | 76 | 1.550 |
Why?
| | Meningeal Neoplasms | 5 | 2022 | 86 | 1.540 |
Why?
| | Glioblastoma | 8 | 2019 | 250 | 1.520 |
Why?
| | Radiosurgery | 4 | 2023 | 299 | 1.120 |
Why?
| | Skull Base Neoplasms | 3 | 2022 | 24 | 1.000 |
Why?
| | Spinal Cord Neoplasms | 2 | 2023 | 36 | 0.980 |
Why?
| | Neurosurgical Procedures | 6 | 2022 | 150 | 0.890 |
Why?
| | Fluorescein | 4 | 2021 | 25 | 0.880 |
Why?
| | Ependymoma | 2 | 2023 | 152 | 0.860 |
Why?
| | Ear, Inner | 1 | 2023 | 39 | 0.840 |
Why?
| | Spinal Neoplasms | 1 | 2023 | 26 | 0.830 |
Why?
| | Psychosurgery | 1 | 2021 | 5 | 0.770 |
Why?
| | Drug Resistant Epilepsy | 1 | 2021 | 45 | 0.720 |
Why?
| | Third Ventricle | 2 | 2021 | 14 | 0.700 |
Why?
| | Arteriovenous Malformations | 1 | 2020 | 24 | 0.700 |
Why?
| | Scalp | 1 | 2020 | 29 | 0.700 |
Why?
| | Laser Therapy | 1 | 2021 | 99 | 0.690 |
Why?
| | Neuroendoscopy | 2 | 2020 | 14 | 0.680 |
Why?
| | Robotic Surgical Procedures | 1 | 2021 | 86 | 0.680 |
Why?
| | Central Nervous System Cysts | 1 | 2019 | 10 | 0.660 |
Why?
| | Antibiotics, Antineoplastic | 1 | 2019 | 110 | 0.630 |
Why?
| | Neurologic Examination | 1 | 2019 | 113 | 0.620 |
Why?
| | Olfaction Disorders | 1 | 2019 | 50 | 0.610 |
Why?
| | Smell | 1 | 2019 | 111 | 0.590 |
Why?
| | Bleomycin | 1 | 2019 | 228 | 0.590 |
Why?
| | Biopsy | 3 | 2021 | 1024 | 0.570 |
Why?
| | Tectum Mesencephali | 1 | 2015 | 1 | 0.510 |
Why?
| | Ventriculostomy | 1 | 2015 | 17 | 0.510 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2022 | 850 | 0.490 |
Why?
| | Astrocytoma | 1 | 2015 | 106 | 0.480 |
Why?
| | Retrospective Studies | 15 | 2023 | 12521 | 0.450 |
Why?
| | Exosomes | 1 | 2014 | 92 | 0.430 |
Why?
| | Treatment Outcome | 11 | 2023 | 9049 | 0.430 |
Why?
| | Trigeminal Neuralgia | 2 | 2023 | 10 | 0.420 |
Why?
| | Drug Delivery Systems | 1 | 2015 | 295 | 0.410 |
Why?
| | Preoperative Care | 1 | 2014 | 319 | 0.380 |
Why?
| | Severity of Illness Index | 1 | 2019 | 2537 | 0.380 |
Why?
| | Proteome | 1 | 2014 | 337 | 0.370 |
Why?
| | Humans | 31 | 2023 | 114043 | 0.320 |
Why?
| | Quality of Life | 4 | 2022 | 2343 | 0.280 |
Why?
| | Craniotomy | 2 | 2019 | 68 | 0.270 |
Why?
| | Transcription Factors | 1 | 2014 | 1525 | 0.270 |
Why?
| | Neoplasms | 2 | 2022 | 2086 | 0.260 |
Why?
| | Antineoplastic Agents | 1 | 2015 | 1875 | 0.230 |
Why?
| | Glioma | 2 | 2018 | 285 | 0.220 |
Why?
| | Spinal Cord | 2 | 2023 | 344 | 0.210 |
Why?
| | Skull Base | 2 | 2021 | 39 | 0.210 |
Why?
| | Male | 14 | 2023 | 55396 | 0.200 |
Why?
| | Edema | 1 | 2023 | 119 | 0.200 |
Why?
| | Hematoma, Subdural, Chronic | 1 | 2021 | 1 | 0.200 |
Why?
| | Facial Nerve | 1 | 2022 | 30 | 0.190 |
Why?
| | Magnetic Resonance Imaging | 3 | 2018 | 3039 | 0.190 |
Why?
| | Signal Transduction | 1 | 2014 | 4501 | 0.190 |
Why?
| | Postoperative Period | 2 | 2021 | 288 | 0.190 |
Why?
| | Spine | 1 | 2023 | 136 | 0.190 |
Why?
| | Cavernous Sinus | 1 | 2021 | 14 | 0.190 |
Why?
| | Corpus Callosum | 1 | 2021 | 56 | 0.190 |
Why?
| | Neurosurgery | 1 | 2021 | 26 | 0.180 |
Why?
| | Female | 13 | 2023 | 59325 | 0.180 |
Why?
| | Central Nervous System Vascular Malformations | 1 | 2020 | 23 | 0.180 |
Why?
| | Cerebral Arteries | 1 | 2020 | 55 | 0.170 |
Why?
| | Middle Aged | 9 | 2023 | 26605 | 0.160 |
Why?
| | Surgical Flaps | 1 | 2020 | 121 | 0.160 |
Why?
| | Adult | 8 | 2023 | 30375 | 0.160 |
Why?
| | Antineoplastic Agents, Alkylating | 2 | 2016 | 68 | 0.160 |
Why?
| | Dacarbazine | 2 | 2016 | 99 | 0.160 |
Why?
| | Face | 1 | 2020 | 163 | 0.160 |
Why?
| | Embolization, Therapeutic | 1 | 2020 | 178 | 0.150 |
Why?
| | Magnetic Resonance Angiography | 1 | 2020 | 221 | 0.150 |
Why?
| | Aged | 7 | 2021 | 18969 | 0.140 |
Why?
| | Education, Medical | 1 | 2020 | 214 | 0.140 |
Why?
| | Endovascular Procedures | 1 | 2020 | 267 | 0.130 |
Why?
| | Aged, 80 and over | 4 | 2023 | 6306 | 0.130 |
Why?
| | Patient Care Team | 1 | 2020 | 517 | 0.130 |
Why?
| | Cranial Irradiation | 1 | 2015 | 66 | 0.120 |
Why?
| | Radiotherapy, Adjuvant | 1 | 2016 | 182 | 0.120 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 1 | 2016 | 111 | 0.120 |
Why?
| | Image Interpretation, Computer-Assisted | 1 | 2017 | 224 | 0.120 |
Why?
| | Tissue Distribution | 1 | 2015 | 285 | 0.120 |
Why?
| | Neoplasm Grading | 1 | 2015 | 241 | 0.120 |
Why?
| | Microscopy | 1 | 2015 | 125 | 0.120 |
Why?
| | Extracellular Space | 1 | 2014 | 116 | 0.110 |
Why?
| | Ligation | 1 | 2014 | 75 | 0.110 |
Why?
| | Nose | 1 | 2014 | 55 | 0.110 |
Why?
| | Clinical Competence | 1 | 2020 | 882 | 0.110 |
Why?
| | Adolescent | 2 | 2021 | 17800 | 0.100 |
Why?
| | Receptors, Antigen, T-Cell | 1 | 2016 | 615 | 0.100 |
Why?
| | Disease Progression | 1 | 2019 | 2371 | 0.100 |
Why?
| | Arteries | 1 | 2014 | 246 | 0.100 |
Why?
| | RNA-Binding Proteins | 1 | 2014 | 344 | 0.100 |
Why?
| | Brain | 1 | 2023 | 2355 | 0.090 |
Why?
| | Immunotherapy | 1 | 2015 | 473 | 0.090 |
Why?
| | Clinical Trials as Topic | 1 | 2015 | 926 | 0.090 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2014 | 1142 | 0.080 |
Why?
| | Proteomics | 1 | 2014 | 815 | 0.080 |
Why?
| | Biomarkers, Tumor | 1 | 2015 | 1032 | 0.080 |
Why?
| | Transcription, Genetic | 1 | 2014 | 1310 | 0.080 |
Why?
| | DNA-Binding Proteins | 1 | 2014 | 1311 | 0.070 |
Why?
| | Pain | 2 | 2023 | 701 | 0.070 |
Why?
| | Young Adult | 2 | 2016 | 10444 | 0.060 |
Why?
| | Sella Turcica | 1 | 2022 | 13 | 0.050 |
Why?
| | Trephining | 1 | 2021 | 1 | 0.050 |
Why?
| | Hydroxyapatites | 1 | 2021 | 12 | 0.050 |
Why?
| | Esthetics | 1 | 2021 | 37 | 0.050 |
Why?
| | Durapatite | 1 | 2021 | 35 | 0.050 |
Why?
| | Supratentorial Neoplasms | 1 | 2021 | 17 | 0.050 |
Why?
| | Journal Impact Factor | 1 | 2021 | 27 | 0.050 |
Why?
| | Bibliometrics | 1 | 2021 | 43 | 0.040 |
Why?
| | Personal Satisfaction | 1 | 2021 | 181 | 0.040 |
Why?
| | Recurrence | 1 | 2021 | 925 | 0.040 |
Why?
| | Margins of Excision | 1 | 2016 | 29 | 0.030 |
Why?
| | Intraoperative Period | 1 | 2016 | 51 | 0.030 |
Why?
| | Karnofsky Performance Status | 1 | 2016 | 36 | 0.030 |
Why?
| | Cell Count | 1 | 2017 | 303 | 0.030 |
Why?
| | Tumor Burden | 1 | 2017 | 258 | 0.030 |
Why?
| | Surgery, Computer-Assisted | 1 | 2016 | 61 | 0.030 |
Why?
| | New York | 1 | 2015 | 105 | 0.030 |
Why?
| | Radiotherapy Dosage | 1 | 2015 | 243 | 0.030 |
Why?
| | Age Distribution | 1 | 2015 | 341 | 0.030 |
Why?
| | Sex Distribution | 1 | 2015 | 336 | 0.030 |
Why?
| | Chemoradiotherapy | 1 | 2015 | 187 | 0.030 |
Why?
| | Animals | 1 | 2015 | 31565 | 0.030 |
Why?
| | Contrast Media | 1 | 2016 | 347 | 0.030 |
Why?
| | Combined Modality Therapy | 1 | 2016 | 1117 | 0.030 |
Why?
| | Survival Analysis | 1 | 2016 | 1206 | 0.030 |
Why?
| | Survival Rate | 1 | 2015 | 1638 | 0.020 |
Why?
| | Postoperative Complications | 1 | 2021 | 2122 | 0.020 |
Why?
| | Algorithms | 1 | 2017 | 1469 | 0.020 |
Why?
| | Prevalence | 1 | 2015 | 2247 | 0.020 |
Why?
| | Biomarkers | 1 | 2016 | 3397 | 0.020 |
Why?
| | Child | 1 | 2022 | 18400 | 0.010 |
Why?
| | Risk Factors | 1 | 2015 | 8614 | 0.010 |
Why?
|
|
Ung's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|